Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02500667 · ClinicalTrials.gov registry record · Phase 1
A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects
A Phase 1 study, sponsored by Nivalis Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02500667 is a Phase 1 study that has completed, run by Nivalis Therapeutics. The registered enrollment target is 15 participants.
The verdict
NCT02500667, a Phase 1 study, has completed, sponsored by Nivalis Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The present study is designed to assess the effects of Rifampin on the pharmacokinetics of N91115 in healthy subjects.
Interventions
- DRUG Rifampin
- DRUG N91115
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02500667
The ClinicalTrials.gov registry entry for NCT02500667 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nivalis Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rifampin is the first listed.
NCT02500667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02500667 about?
NCT02500667 is a clinical study titled "A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects". The present study is designed to assess the effects of Rifampin on the pharmacokinetics of N91115 in healthy subjects.
What is the current status of trial NCT02500667?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2015-06. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02500667?
The interventions under investigation include: Rifampin (DRUG), N91115 (DRUG).
Who is sponsoring clinical trial NCT02500667?
This trial is sponsored by Nivalis Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.